HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a price target of $51.
September 27, 2023 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcturus Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $51.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Arcturus Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100